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Drug shortages pose a clear detriment to antimicrobial stewardship (AS) efforts. Our
objective was to evaluate the effect of a piperacillin-tazobactam shortage on meropenem
use,  related costs, and associated changes in AS activity. A quasi-experimental quality
improvement review compared adult patients receiving meropenem ≥72 h three months
pre-shortage and three months during the shortage. 320 patients were included (pre-
shortage: 103; shortage: 217). Baseline characteristics were similar, but the length of stay was
slightly longer in pre-shortage [19 (11–32) days] versus shortage [16 (11–32) days] (p = 0.094). In
pre-shortage and shortage, median days of therapy and estimated meropenem cost were 7
(5–11) and 7 (5–10) and $309.93 ($173.60–$507.03) and $255.30 ($204.24–$424.31), respectively
(p  = 0.411 and p = 0.050). Frequency of ID consultation was similar (16.8% in pre- and 25.3%
in  shortage, p = 0.091). AS interventions increased during the shortage period (99 in pre-
shortage and 205 in shortage). De-escalation occurred in 19.4% versus 32.7% of the patients in
pre-shortage and shortage (p = 0.014). The piperacillin-tazobactam shortage was associated
with  a 111% increase in meropenem prescriptions despite active AS, but was not associated
with changes in mortality, length of therapy, or meropenem costs. AS should be aware that
shortages may require proactive countermeasures to avoid inappropriate antimicrobial useduring shortage periods.
© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
prescriber must use an alternative agent”. From 2007 to 2011,ccording to the American Society of Health-Systems Phar-
acists (ASHP), a drug shortage is deﬁned as “a supply
ssue that affects how a pharmacy prepares or dispenses
 drug or product that inﬂuences patient care such that a
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1over).
the numbers of new and ongoing drug shortages, including
anti-infectives, increased.2,3 As a result, the Food and Drug
Administration developed a strategic plan intended to prevent
lsevier Editora Ltda. This is an open access article under the CC
.
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Table 1 – Patient demographics.
Variable
Presented as n (%)
or median (IQR)
Pre-
shortage
group
(n  = 103)
Shortage
group
(n = 217)
p-Value
Age, years 57 (38–67) 58 (44–70) 0.19
Gender, male 58 (56.3) 124 (57.1) 0.36
Co-morbid conditions
Diabetes 43 (41.7) 69 (31.8) 0.07
Dyslipidemia 21 (20.4) 42 (19.4) 0.80
Hypertension 63 (61.2) 133 (61.3) 0.98
ESRD 14 (13.6) 34 (16.9) 0.65
HIV 1 (1.0) 10 (4.0) 0.18
Cancer 27 (26.2) 43 (19.8) 0.18
Transplant 6 (5.8) 15 (7.5) 0.73
Source of infection
Bacteremia 18 (17.5) 27 (12.4) 0.23
Respiratory 42 (40.8) 87 (40.1) 0.91
Abdominal 15 (14.6) 34 (15.7) 0.80
Urinary 18 (17.5) 31 (14.3) 0.46632  b r a z j i n f e c t d 
and mitigate drug shortages.4,5 Additionally, the Generating
Antibiotic Incentives Now (GAIN) and Antibiotic Development
to Advance Patient Treatment (ADAPT) Acts were established
in 2012 and 2013, respectively, to provide incentives, including
fast-track approval, to add new anti-infectives to the market.
Although the number of new drug shortages has begun to
decline since 2011, approximately 300 drugs annually remain
on active/ongoing shortages.6 Shortages affecting antimicro-
bial agents, including those used for acute, life-threatening
illnesses, present some of the largest challenges for clinicians.
With infections caused by Gram-negative pathogens on the
rise, our antimicrobial stewardship program (ASP) sought to
preserve meropenem usage for patients with an ASP-deemed
appropriate indication (infection with or history of infection
with extended-spectrum beta-lactamase-producing organism
or an organism resistant to third-generation cephalosporins,
clinical/microbiological treatment failure requiring escala-
tion). Through implementation of this targeted stewardship
audit and feedback intervention, meropenem usage declined
by more  than 30% (unpublished data). In the ﬁrst quarter
of 2015, however, piperacillin-tazobactam went on shortage.
Therefore, the objective of this study was to determine the
impact of a piperacillin-tazobactam shortage on the usage of
meropenem, clinical and economic outcomes, and associated
ASP activities.
This quasi-experimental quality improvement retrospec-
tive review was conducted at a large academic medical center
(700+ beds) as part of routine antimicrobial stewardship
efforts in compliance with Institutional Review Board require-
ments. A convenience sample of meropenem utilization
three months prior to the ASHP-denoted national short-
age of piperacillin-tazobactam was compared to meropenem
use during the three months during the shortage. A one
month washout period in which the stock of piperacillin-
tazobactam was depleted occurred in January. Patients were
identiﬁed using TheraDoc Clinical Surveillance Software (Pre-
mier, Inc.; Salt Lake City, UT). Data were collected from
patient charts using the EPIC Systems electronic charting
system (Madison, WI). All adult patients that received ≥72
consecutive hours of meropenem therapy were included.
Patients less than 18 years of age, those who died within
72 h of therapy initiation, or duplicate patients (hospital-
izations other than the ﬁrst within the time period) were
excluded. Demographic characteristics and medication allergy
information were collected for each patient. Information
regarding hospital course, including length of stay, loca-
tion (intensive care unit at any time during receipt of
meropenem vs. ward), in-hospital mortality, 30-day read-
mission, and whether an infectious disease (ID) consult
occurred, were collected. Dose, duration, and frequency
of meropenem administration, along with comorbidities,
indication for meropenem treatment, and adverse drug
reactions were collected. Any cultured organisms were
recorded, along with culture source. We also recorded whether
de-escalation to another beta-lactam was possible (based
on timing of culture results) and whether de-escalation
occurred. Finally, total number of documented interventions
of ASP activity, including chart review prompted by tar-
geted drug alerts, antimicrobial de-escalation or antimicrobial
dosage/frequency changes during these time frames were alsoSkin/soft tissue 8 (7.8) 24 (11.1) 0.36
Empiric 37 (35.9) 68 (31.3) 0.41
recorded. ASP interventions were irrespective of ID consul-
tation and recommendations from either do not routinely
overlap.
The primary outcomes were meropenem usage rates,
clinical (mortality, length of stay and ICU status) and
meropenem-related cost analysis, and associated ASP activ-
ities in each period. Secondary outcomes included number
of infectious diseases consults and prescribing trends based
upon resistance. Categorical data was analyzed utilizing Chi-
square or Fisher’s Exact tests. Mann–Whitney U and Student’s
t-test were performed for continuous data. All statistical anal-
yses were performed using SPSS Statistical Software (Release
22, SPSS, Inc., Chicago, IL, USA). A p-value ≤0.05 was consid-
ered statistically signiﬁcant.
A total of 771 charts were screened for review. After
excluding 451 patients (10 patients <18 years old, 169 <72 h
of consecutive meropenem therapy, 272 duplicate patients),
320 patients were included in this study, with 103 in
the pre-treatment group and 217 in the shortage group.
The median (IQR) age of the cohort was 57 (43–68) years
of age. Gender was predominately male (56.9%) and the
majority of the patients were African American (57.0%). Base-
line characteristics and demographics were similar between
the two groups, with the most common comorbid condi-
tions being hypertension and diabetes (Table 1). A dramatic
111% increase in meropenem usage was observed from the
pre-shortage to shortage arms. Overall, no mortality differ-
ence was observed between the pre-shortage and shortage
groups (24.3% and 22.6%, respectively (p = 0.74)). Intensive
care unit (ICU) status was comparable in both arms, with
ICU admittance representing 62.8% of the population. In the
pre-shortage group, median length of stay was statistically
longer than in the shortage group (p = 0.02) (Table 2). The
median (IQR) days of therapy between groups was compa-
rable at 7 (5–11) and 7 (5–10) days, respectively (p = 0.411).
ID consultation was performed in 16.8% and 25.3% of the
patients in the pre- and shortage arms (p = 0.091) with
b r a z j i n f e c t d i s . 2 0 1 
Table 2 – Patient outcomes.
Outcome
Presented as n (%)
or median (IQR)
Pre-
shortage
group
(n  = 103)
During
shortage
group
(n = 217)
p-Value
Length of stay (days) 19 (11–32) 16 (9–24) 0.02
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our study is not without limitations. First, inclusion crite-ICU admission 70 (68.0) 131 (60.4) 0.12
Mortality 25 (24.3) 49 (22.6) 0.74
ncreased de-escalation occurring in the shortage patients
19.4% vs 32.7%, respectively (p = 0.014)). The most frequently
tilized antimicrobial classes upon de-escalation in either
roup were the ﬂuoroquinolones and beta-lactams. Over-
ll, estimated median meropenem cost per patient, despite
o difference in dosing, was $309.93 ($173.60–$507.03) and
255.30 ($204.24–$424.31) in the pre- and shortage group-
ngs (p = 0.05). While many  isolates were collected, the
redominant pathogens identiﬁed were Escherichia coli (30.6%),
lebsiella pneumoniae (16.3%) and Enterobacter spp. (10.0%)
or both groups. The pre-shortage group had a higher fre-
uency of patients with multiple pathogens isolated (17.5%
s. 8.8%), increased frequency of ESBL organisms (17.5% vs.
.5%), and decreased opportunity for de-escalation (75.5%
s. 88.5%). Overall ASP interventions increased during the
hortage period (99 in pre-shortage and 205 in short-
ge).
In this study, a piperacillin-tazobactam shortage was
ssociated with a 111% increase in meropenem prescrip-
ions despite active antimicrobial stewardship, but was not
ssociated with changes in mortality, length of therapy, or
eropenem costs. During the shortage period, ASP interven-
ions and ID consults increased and ESBL rates decreased.
here was no difference in in-hospital mortality or length
f meropenem therapy between the pre-shortage and short-
ge groups. However, in the pre-shortage group, length of
tay and meropenem drug costs were numerically higher.
his may be attributable to the increased number of resis-
ant organisms or the increased length of stay in this period.
n the shortage group, ID was consulted more  often and
he ASP recorded more  than twice the number of over-
ll interventions. The increased ASP presence during the
hortage period may be responsible for the increase in de-
scalation.
In a study of the impact of a 2002 piperacillin-
azobactam shortage on antimicrobial prescribing rates,
endez and colleagues found that, while piperacillin-
azobactam use decreased, ceftriaxone, levoﬂoxacin, metroni-
azole, ampicillin-sulbactam, and ticarcillin-clavulanate use
ncreased.7 Although this study did a thorough job evaluat-
ng the impact of an antimicrobial shortage on other agents,
arbapenem usage rates were variable depending on the anal-
sis used (slight decrease by charged dose, slight increase by
ram usage). This is in contrast to our ﬁndings of a signiﬁcant
ncrease in carbapenem usage (by number of prescriptions)
uring the shortage period.
In a similar study, Pluss-Suard and colleagues eval-ated changes in broad-spectrum antibiotics following a
efepime shortage.8 Investigators found signiﬁcant increases
n piperacillin-tazobactam and meropenem in hospitals with6;2 0(6):631–634 633
deﬁnitive and transient interruptions in cefepime supply,
respectively, and associated signiﬁcant increases in overall
cost. Similar to these investigators, we found that, in the midst
of a piperacillin-tazobactam shortage, our meropenem rates
increased. In contrast to this study, though, our meropenem
drug costs were lower during the shortage period. This may
be due to the diligence and increased de-escalation efforts of
our ASP.
Finally, in a study of the impact of an intravenous trimetho-
prim/sulfamethoxazole shortage on treatment outcomes with
Pneumocystis jirovecii pneumonia, Dilworth and colleagues
found that more  patients experienced treatment failure, wors-
ening clinical status, and had slightly longer length of stay
during the shortage as compared to the pre-shortage period.9
It was suggested that, although the negative impact on patient
outcomes was immediate, collaboration between pharmacists
and physician caregivers improved outcomes and lessened
the global impact of the shortage. The patient outcomes
in this study are in contrast to our ﬁnding of a signiﬁ-
cantly decreased length of stay during the pre-shortage group
and the ﬁndings of no difference between groups in length
of therapy, days of therapy, and ICU status. However, the
increase in ASP interventions and ID consults in our study
are likely similar to Dilworth’s reported collaboration between
pharmacists and physicians, which may be responsible for
the overall similarity between outcomes in our evaluated
groups.
Other institutions have also seen beneﬁt of collabora-
tion between healthcare providers, suggesting that combined
efforts are needed to address and sufﬁciently respond to drug
shortages.9,10 Without the diligence and pre-emptive activity
by our ASP, the impact of the piperacillin-tazobactam short-
age on meropenem use at this institution may have been
more drastic. Moving forward, hospitals should consider hav-
ing a shortage-response plan in place, similar to the concept
of disaster management plans many  hospitals utilize. Con-
cepts such as our EPIC alternative therapy pop-up, automatic
alternative substitution by the pharmacy department, and
prescriber education may also be beneﬁcial. In the case of
antimicrobial shortages, the involvement of an antimicrobial
stewardship program is essential to protect the welfare of the
patient while deciding how best to allocate the shorted med-
ications.
Similar to the challenges with infection control and
containment in developing or low-income countries,11,12
antimicrobial shortages may present challenges for appro-
priate management of infections in these regions. Similar
to the challenge of containing Ebola that was seen in Africa
recently,12 a lack of speciﬁc treatments and reliable interven-
tions in resource-poor countries, including those instigated by
an antimicrobial shortage, may be highly impactful for patient
care. Antimicrobial stewardship efforts to substitute the most
appropriate available therapies, even without a formal ASP,
should be undertaken in these situations in order to lessen
the impact on clinical outcomes.
As with other retrospective quasi-experimental reviews,ria included meropenem use for 72 h, which does not
account for courses of meropenem on which the ASP
intervened at 24 or 48 h. Next, although we  know that
i s . 2 0
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piperacillin-tazobactam use in the shortage period was
negligible, use in the pre-shortage period was not mon-
itored by the ASP or recorded. In addition, usage rates
of other comparable broad-spectrum regimens on formu-
lary (cefepime or ceftriaxone plus metronidazole) were
not obtained for either period. Finally, culture data were
recorded for the individual patients included, but resistance
data for the institution as a whole (carbapenem-resistant
enterobacteriaceae, Clostridium difﬁcile, vancomycin-resistant
enterococci) are not available for these periods. Lastly,
we only report bivariate analyses. Therefore, the effects
related to unique populations such as oncologic or ICU
admitted patients may be diluted by the overall popula-
tion.
Antimicrobial shortages have an impact on the prescrib-
ing habits of clinicians irrespective of an established ASP.
Although meropenem use increased dramatically during the
piperacillin-tazobactam shortage period, ASP interventions,
ID consults, and overall de-escalation also increased, mor-
tality rates and length of therapy remained consistent, and
average meropenem cost per course decreased. With the
potential for adverse clinical outcomes associated with these
shortages, hospitals should consider more  aggressive, alter-
native strategies to avoid inappropriate antimicrobial usage
during these times.
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